Bessemer Group
PTLA

Bessemer Group’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Bessemer Group’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-299
Closed -$16K – 1865
2017
Q3 		$16K Hold
299
– – ﹤0.01% 1534
2017
Q2 		$17K Buy
+299
New +$12K ﹤0.01% 1514
2014
Q4 		– Sell
-22,630
Closed -$572K – 1582
2014
Q3 		$572K Buy
+22,630
New +$596K ﹤0.01% 561

Other funds holding PTLA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.65B AUM 23.83% 1-Year Est. Return

Bessemer Group's PTLA Position: Q4 2017 in Review

Bessemer Group sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q4 2017, closing a stake of 299 shares — an estimated $16K sold.

Bessemer Group first reported a position in PTLA in Q3 2014 and held it in 3 quarters. The position peaked at $572K in Q3 2014. 215 funds tracked by Wall St. Rank hold PTLA as of Q4 2017.

  • Bessemer Group reported no remaining Portola Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
  • Bessemer Group sold 299 Portola Pharmaceuticals, Inc. shares in Q4 2017, an estimated $16K.
  • Bessemer Group first reported a position in Portola Pharmaceuticals, Inc. in Q3 2014 and held it in 3 quarters.
  • Bessemer Group's Portola Pharmaceuticals, Inc. position peaked at $572K in Q3 2014.
  • 215 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q4 2017.

Based on Bessemer Group's 13F filing for Q4 2017, filed 30 Jan 2018.